Correction: Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial Manner.
J Immunol
; 200(7): 2509-2510, 2018 04 01.
Article
en En
| MEDLINE
| ID: mdl-29475989
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Año:
2018
Tipo del documento:
Article